Group 1 - The Zhejiang Social Security Science and Technology Innovation Equity Investment Fund has been successfully established, marking a collaboration between the National Social Security Fund Council and local government [1] - The fund has an initial scale of 50 billion yuan, targeting key industries such as artificial intelligence, new generation information technology, high-end equipment, new materials, and biomedicine [3] - The fund aims to create a comprehensive fund system covering the entire chain from "achievement transformation - innovation acceleration - industrial upgrading" [3] Group 2 - The fund will operate under principles of marketization, rule of law, and professionalism, aligning closely with national industrial policies and the strategic deployment of the Zhejiang provincial government [3] - The fund seeks to mobilize more social capital into the technology innovation sector, supporting the transformation of traditional industries and the cultivation of emerging industries [3] - The fourth Davos Global Fund of Funds Summit will be held in January 2026, focusing on multilateral dialogue in the global fund of funds industry [4][6]

11月21日，三生国健盘中下跌2.04%，截至10:23，报64.28元/股，成交1.24亿元，换手率0.31%，总市值 396.47亿元。 资金流向方面，主力资金净流入200.37万元，特大单买入951.74万元，占比7.70%，卖出511.46万元，占 比4.14%；大单买入2717.60万元，占比21.98%，卖出2957.52万元，占比23.92%。 三生国健今年以来股价涨201.83%，近5个交易日跌11.18%，近20日涨17.31%，近60日涨20.86%。 今年以来三生国健已经7次登上龙虎榜，最近一次登上龙虎榜为11月3日。 三生国健所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、融资融 券、增持回购、中盘、抗癌药物等。 截至9月30日，三生国健股东户数1.12万，较上期减少12.77%；人均流通股55060股，较上期增加 14.64%。2025年1月-9月，三生国健实现营业收入11.16亿元，同比增长18.80%；归母净利润3.99亿元， 同比增长71.15%。 分红方面，三生国健A股上市后累计派现1.27亿元。 机构持仓方面，截止2025年9月30日，三生国健 ...

Core Viewpoint - Changchun High-tech's stock has experienced a decline in recent trading sessions, with significant net outflows of capital and a decrease in both revenue and net profit year-on-year [1][2]. Financial Performance - For the period from January to September 2025, Changchun High-tech reported operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60% [2]. - The net profit attributable to shareholders was 1.165 billion yuan, reflecting a substantial year-on-year decline of 58.23% [2]. Stock Market Activity - On November 21, Changchun High-tech's stock price fell by 2.01%, trading at 99.65 yuan per share, with a total market capitalization of 40.651 billion yuan [1]. - The stock has seen a year-to-date increase of 2.86%, but has declined by 4.69% over the last five trading days and 15.44% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.63% to 104,100, while the average number of circulating shares per person increased by 4.85% to 3,840 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, increasing its holdings by 1.307 million shares [3]. Dividend Distribution - Since its A-share listing, Changchun High-tech has distributed a total of 4.791 billion yuan in dividends, with 3.259 billion yuan distributed over the past three years [3].

Core Viewpoint - Nocare Biopharma's stock has experienced fluctuations, with a year-to-date increase of 92.83% but a recent decline of 6.55% over the past five trading days [1] Company Overview - Nocare Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Financial Performance - For the period from January to September 2025, Nocare Biopharma reported revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, with an average of 0 circulating shares per person [2] - The top ten circulating shareholders include several new entrants, such as Wanjiayou Xuan and Ping An Healthcare, while some previous shareholders have exited the list [3]

Core Viewpoint - Zai Lab's stock price has shown significant volatility, with a year-to-date increase of 64.82%, but a recent decline of 3.11% over the past five trading days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Company Overview - Zai Lab, established on March 18, 2009, and listed on January 23, 2020, is based in Kunshan, Jiangsu Province, focusing on the research, production, and sales of chemical and biological new drugs [1]. - The company's main revenue source is pharmaceuticals, accounting for 99.97% of its business, with minimal contributions from intermediates and asset leasing [1]. Financial Performance - For the period from January to September 2025, Zai Lab reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, showing a slight increase in loss of 4.58% compared to the previous period [2]. Shareholder Structure - As of September 30, 2025, Zai Lab had 8,809 shareholders, a slight increase of 0.16% from the previous period. The average number of circulating shares per shareholder decreased by 0.16% to 30,049 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A, with varying changes in their holdings [2].

卢载宪表示，很高兴到山东访问并出席韩鲁交流活动。希望深化与山东地方和企业间交流，巩固提 升传统产业合作，深化拓展智能制造、再生能源、文化消费等新兴领域合作，进一步密切友好关系。 省领导刘强、邓云锋、宋军继参加。（记者 李子路 于新悦） 11月19日下午，省委书记林武在山东大厦会见了韩国新任驻华大使卢载宪。 林武对卢载宪大使的到来表示热烈欢迎。他说，大使先生这次来山东访问并出席中国（山东）—韩 国友好周活动，体现了对山东的重视和深厚情谊。前不久，习近平主席赴韩国出席APEC会议并进行国 事访问，与李在明总统举行会谈，达成重要共识，为山东与韩国地方合作指明方向。山东是中国的人口 大省、文化大省、经济大省，我们正按照习近平主席重要指示要求，锚定"走在前、挑大梁"，加快建设 绿色低碳高质量发展先行区，打造高水平对外开放新高地，努力成为北方地区经济重要增长极，奋力谱 写中国式现代化山东篇章。近年来，山东与韩国地方人员、经贸往来日益密切，双方合作基础坚实、势 头良好。希望双方以两国元首重要共识为指引，进一步密切友好往来，促进双向投资，加强人工智能、 生物医药、医养健康、现代农业、文化旅游等领域合作，更好促进互利互惠、实现 ...

Core Viewpoint - The 19th Shenzhen International Financial Expo highlights optimism regarding China's economic future, driven by new technological revolutions and internal economic adjustments [1] Economic Cycle Analysis - The difficulties affecting China's economy, such as issues in the real estate sector, are diminishing, while new growth drivers like artificial intelligence are strengthening [1] - The ongoing deepening of reform and opening-up policies continues to release positive forces for economic recovery [1] - The challenging phase of the Chinese economy is approaching its end [1] Technological Revolution Perspective - A new technological revolution, characterized by advancements in artificial intelligence and biomedicine, is progressing rapidly [1] - Unlike previous technological and industrial revolutions where China was a bystander, it is now a participant and leader in this new wave [1] - The new economy is expected to significantly influence and dominate China's future development [1] Long-term Strategic Focus - Emphasizing the importance of self-improvement and addressing internal challenges is crucial for enhancing competitiveness [1] - The future will favor those who strengthen themselves and effectively resolve their issues [1] - A brighter future is anticipated for entities that can elevate their competitiveness in the face of global changes [1]

21世纪经济报道记者 黄子潇 深圳报道 二是打造全球一流的创新资本形成中心，重点打造四个一流：世界一流交易所——支持深交所发展成为 服务全国战略性新兴产业的多层次债券市场，支持深圳股权交易中心加快推动PE/VC份额转让试点；一 流投行——培育引导证券机构坚持功能型、集约型、专业化、特色化发展方向，坚持服务科技创新、支 持辖区头部证券机构通过并购重组等做大做优做强；一流投资机构——坚持投资者利益优先，坚持价值 投资，打造更具竞争力的投研体系，全面提升机构核心竞争力；一流的配套服务——高水平打造香蜜 湖、前海、深圳湾西丽湖风投创投集聚区，发挥深圳创投日等产融对接。 11月19日上午，第十九届深圳国际金融博览会（深圳金博会）举行开幕式。 会上，深圳市人民政府副秘书长吴坤生表示，面向"十五五"新征程，深圳将以建设全球重要影响力的产 业金融中心为目标，重点聚焦六个方面发力。 分别为：打造全球一流的科技产业金融互促发展高地、打造全球一流的创新资本形成中心、打造全球一 流的金融科技中心、打造全球一流的跨境人民币服务高地、打造全球一流的财富管理中心、打造全球一 流的金融安全示范地。 今年2月，2025年深圳市政府工作报告首次 ...

分享结束后，圆桌讨论环节的问答氛围热烈。参会企业代表围绕自身赴港上市规划、业务发展瓶颈等问题积极提问，三位专家针对这些问题逐一回答，提 供了个性化解决方案。 2025年11月18日，由北京股权交易中心有限公司（以下简称北股交）、北京京东方空间数智科技服务有限公司联合主办，天风国际证券集团有限公司、中 伦律师事务所、北京外企人力资源服务有限公司协办的"赴港上市，智赢未来"港股IPO及香港资本市场分析交流会顺利举办。活动聚焦企业赴港上市核心 需求，汇聚证券、法律、人力资源领域专家，吸引28家企业代表参会，覆盖人工智能、生物医药、智能制造等多个前沿赛道。 北京外企人力资源服务有限公司胡晓星围绕港股上市人力资源合规展开分享，介绍了赴港上市企业在招聘、入职、在职、离职人力资源管理全周期的合规 要点及相关法定义务，还讲解了香港《雇佣条例》下的用工政策、三类人才入境计划，以及FESCO的出海核心服务和服务中企出海的丰富经验。 本次交流会通过精准解读政策、拆解实操难题、搭建资源平台，有效破解了企业赴港上市的信息不对称问题。作为北京市唯一的区域性股权市场运营机 构，北股交始终聚焦企业发展需求，依托北京"专精特新"专板等特色板块 ...

Core Viewpoint - The article emphasizes the new opportunities in investment during the "14th Five-Year Plan" period, driven by a new factor system, a restructured institutional framework, and an innovative service system in the capital market [1]. Group 1: New Factor System - The new factor system, represented by talent and new assets, is becoming a new driving force for China's economic growth. The "14th Five-Year Plan" highlights the importance of technological innovation and original breakthroughs [2]. - Accumulation of technological factors will enable breakthroughs in future industries such as artificial intelligence, biomedicine, hydrogen energy, nuclear fusion, embodied intelligence, and 6G mobile communication [2]. - Data factors will drive economic growth by transforming consumption channels and habits, leading to new consumption patterns such as service consumption, emotional consumption, and integrated consumption [2]. Group 2: New Institutional Framework - The capital market is expected to enhance its quality and capacity under the guidance of policies aimed at activating the market and coordinating investment and financing functions [3]. - Reforms in the capital market's basic systems will significantly improve market inclusiveness and adaptability, with a focus on deepening reforms in the Sci-Tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange [3]. - The formation of a healthy market ecosystem will enhance the attractiveness of the Chinese market, promoting mutual constraints and cooperation among institutional investors, intermediaries, listed companies, and retail investors [3]. Group 3: New Service System - The company is accelerating reforms in its organizational structure, management model, and business system to adapt to changes in the economic landscape, focusing on a comprehensive service system [4]. - In financing services, the company is developing diversified service solutions that encompass venture capital, IPOs, mergers and acquisitions, refinancing, asset securitization, ESG, and strategic consulting [4]. - The investment service aims to meet diverse asset allocation needs of investors with a robust product offering, while trading services are enhancing liquidity support through innovative products like OTC derivatives, market making, ETFs, and carbon finance [4].